Four years of low dose enzalutamide for metastatic castration-resistant prostate cancer
Jazyk angličtina Země Česko Médium print
Typ dokumentu kazuistiky, časopisecké články
PubMed
33657823
DOI
10.48095/ccko202169
PII: 125896
Knihovny.cz E-zdroje
- Klíčová slova
- castration-resistant, enzalutamide, prostate cancer, prostatic neoplasms, reduced-dose drug use, treatment efficacy, treatment outcomes,
- MeSH
- benzamidy aplikace a dávkování MeSH
- fenylthiohydantoin aplikace a dávkování MeSH
- kalikreiny krev MeSH
- lidé MeSH
- nádory prostaty rezistentní na kastraci krev farmakoterapie patologie radioterapie MeSH
- nitrily aplikace a dávkování MeSH
- prostatektomie MeSH
- prostatický specifický antigen krev MeSH
- protinádorové látky aplikace a dávkování MeSH
- senioři nad 80 let MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- Publikační typ
- časopisecké články MeSH
- kazuistiky MeSH
- Názvy látek
- benzamidy MeSH
- enzalutamide MeSH Prohlížeč
- fenylthiohydantoin MeSH
- kalikreiny MeSH
- KLK3 protein, human MeSH Prohlížeč
- nitrily MeSH
- prostatický specifický antigen MeSH
- protinádorové látky MeSH
BACKGROUND: The management of metastatic castration-resistant prostate cancer involves second-generation antiandrogen therapy, including enzalutamide. The recommended dose of 160mg/day is sometimes difficult to use in elderly patients because of the burden of comorbidities. The usefulness of a low effective dose remains unclear. METHODS: We report the first ever patient, now aged 87 years, who had progressing prostate cancer and was treated at 25% of the recommended dose for over 4 years. RESULTS: The most striking observation is that nothing extraordinary happened. The disease responded without dramatic toxicities. His follow-up has been serene on both aspects of prostate cancer and general health. CONCLUSION: Cautious dosage can have a long-lasting favorable impact in the elderly patient.
Citace poskytuje Crossref.org
